Targeted therapy is emerging pharmacotherapy for cancer. It is a type of precision cancer treatment. Targeted therapy used to treat breast cancer, bladder cancer, colorectal cancer kidney cancer, leukemia, liver cancer, lung cancer, lymphoma and prostate cancer. Targeted therapies are made to find and attack specific areas or substances in cancer cells.
The global targeted therapy market is estimated to be valued at US$ 98.6 Bn in 2021 and is expected to exhibit a CAGR of 9.0% during the forecast period (2021-2028).
Figure 1.Global Targeted Therapy Market in Terms of Value (US$ Billion), By Region, 2021
Strong focus on research and development by market players is estimated to drive the global targeted therapy market growth during the forecast period.
For instance, in 1970, Tamoxifen the first targeted cancer therapy was approved by U.S. Food and Drug Administration. The discovery of oncogenes and tumor suppressor genes, and the completion of human genome sequencing fueled some major advances in treating the cancer. Newly emerging biological and genetic information rapidly prompted the introduction of a large number of new targeted cancer therapies. Thus, key players are investing in the research and development and thereby it is expected to drive the market growth. For instance, Boehringer Ingelheim a pharmaceutical companies announced the initiation of a phase II clinical trial of BI 764198, an inhibitor of TRPC6, a receptor-operated cation channel. This therapy may provide the first potential treatment for COVID-19 related respiratory distress syndrome.
|Base Year:||2020||Market Size in 2021:||US$ 98.6 Bn|
|Historical Data for:||2017 to 2020||Forecast Period:||2021 to 2028|
|Forecast Period 2021 to 2028 CAGR:||9.0%||2028 Value Projection:||US$ 165.4 Bn|
Amgen Inc., GlaxoSmithKline plc, Sanofi, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, AstraZeneca, Seagen Inc., Bayer AG, and Bristol Myers Squibb
|Restraints & Challenges:||
Figure 2. Global Targeted Therapy Market Share (%), By Type, 2021
Strategic development by key market players is anticipated to propel the global targeted therapy market growth over the forecast period.
Strategic development such as acquisition, collaboration, partnership, and others to strengthen the market position is likely expected to boost the growth of market. For instance, in May 2021, Xilio Therapeutics, a biotechnology company, entered into a clinical trial collaboration and supply agreement with Merck outside the U.S. and Canada, to evaluate XTX101, Xilio’s engineered tumor-selective Fc-enhanced, anti-CTLA-4 monoclonal antibody (mAb) product candidate, in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 (programmed death receptor-1) therapy.
Global Targeted Therapy Market – Impact of Coronavirus (COVID-19) Pandemic
COVID-19 causes several challenges to cancer practice, especially to ensure continuity of treatment during this period. It has significantly affected healthcare systems and economies within a short timeframe. Various diagnostic & research centres had to slow their activity due to public health measures. Thus, the emerging cancer research was affected due to the COVID-19.
However, targeted therapy is being evaluated in COVID-19 treatment. Thus, by encouraging clinicians to pursue targeted therapy agents during the pandemic is likely expected to create opportunity during the forecast period.
Global Targeted Therapy Market: Restraint
Cost is a major factor influencing the selection of targeted therapy products. The drugs prescribed in targeted therapy treatment are often prohibitively expensive. Thus, higher cost of therapy is likely to hamper the growth of market. For instance, monthly averages of targeted therapy is US$ 5,000 to US$ 10,000 and annual totals over US$ 100,000.
Major players operating in the global targeted therapy market include Amgen Inc., GlaxoSmithKline plc, Sanofi, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, AstraZeneca, Seagen Inc., Bayer AG, and Bristol Myers Squibb.
Targeted therapy is used individually and in combination with other treatments, such as traditional or standard chemotherapy, surgery, or radiation therapy. It is the foundation of precision medicine. Targeted therapies are divided into two classes such as small molecule medicines and monoclonal antibodies. Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells. Monoclonal antibodies, also known as therapeutic antibodies, are proteins produced in the lab. Most types of targeted therapies help to treat cancer by interfering with specific proteins that help tumors grow and spread throughout the body. They treat cancer in many ways such as helps the immune system destroy cancer cells, stop cancer cells from growing, stop signals that help form blood vessels, cause cancer cell death, deliver cell-killing substances to cancer cells, starve cancer of the hormones it needs to grow. Targeted therapies is approved by the U.S. Food and Drug Administration for various types of cancers. This offers significant benefits to treat the cancer such as alter proteins within cancer cells that cause those cells to die, prevent new blood vessels from forming, which cuts off blood supply to tumor, and others. One of the major advantage of targeted therapy is it helps to reduce cancer treatment-related side effects and improved outcomes.
Increase in awareness regarding the advanced therapeutics to treat cancer leads to facilitate drug development in precision oncology is likely expected to boost the growth of market. For instance, in May 2021, the U.S. Food and Drug Administration had approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer. Furthermore, key players operating in the market are engaged in focusing on expanding the products pipeline and thereby strengthening the market position. This in turn to drive the growth of market. For instance, Xilio Therapeutics, a biotechnology company entered into a clinical trial collaboration and supply agreement with Merck to evaluate XTX101, Xilio’s engineered tumor-selective Fc-enhanced, anti-CTLA-4 monoclonal antibody (mAb) product candidate, in combination with KEYTRUDA.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.